Andy Kilianski, PhD joined ARPA-H in May 2023 from the International AIDS Vaccine Initiative (IAVI), where he served as senior director for emerging infectious diseases. During this time, he led IAVI’s filovirus vaccine portfolio – including vaccines focused on Marburg virus and Sudan virus – while also supporting strategy development and key stakeholder engagement across the entire emerging infectious diseases portfolio. Before joining IAVI, Dr. Kilianski was a senior scientist and Science and Technology manager at the Department of Defense, where he built programs focused on countering emerging biological threats. During the onset of the COVID-19 pandemic, Dr. Kilianski led interdisciplinary teams on the Department of Defense COVID-19 Task Force, which focused on vaccine development, supply chain resilience, and COVID-19 operational data tracking and management. At ARPA-H, he has worked to develop a program that uses novel approach methodologies (NAMs) to advance better therapeutic options. Dr. Kilianski received his doctorate in microbiology and immunology from Loyola University of Chicago, where he studied virus-host interactions important for coronavirus pathogenesis.